All-Stock Merger and Capital Allocation

Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) have agreed to an all-stock, equal-weighted merger. Supernus shareholders will receive 1.5401 shares of Indivior for each share they own, and Indivior shareholders will receive a $1 billion special cash dividend prior to the closing of the transaction. This dividend is not part of the purchase price or an upfront payment but rather a return of capital to Indivior shareholders before the merger. The combined company will have a pro forma revenue base of approximately $2.2 billion and is targeting $125 million in annual cost synergies. Jack Khattar, CEO of Supernus, will lead the combined company, and the operating structure will be reorganized around Supernus' CNS commercialization platform.

Sublocade-Driven Addiction Treatment Business

The key asset, Sublocade, is a buprenorphine extended-release injectable suspension administered once monthly, a mu-opioid receptor partial agonist, and was approved by the FDA on November 30, 2017, for the treatment of moderate-to-severe opioid use disorder. In 2025, Indivior's net sales for Sublocade were $856 million, a 13% increase year-over-year, making it the largest single growth driver for the combined company. The main competitor is Braeburn's weekly and monthly buprenorphine injectable, Brixadi, which was approved by the FDA on May 23, 2023. Oral Suboxone (buprenorphine/naloxone), methadone, and Alkermes' (ALKS) Vivitrol (naltrexone extended-release injectable) are also standard treatment options. Therefore, the potential for revenue growth from the merger depends on the ability to translate the advantages of long-acting injectables into actual prescription market share.

Combination of ADHD, Parkinson's Disease, and Postpartum Depression Portfolios

Supernus' marketed growth driver, Qelbree, is a viloxazine extended-release capsule that modulates norepinephrine reuptake and was approved by the FDA in 2021 for children and adolescents and in 2022 for adults with ADHD. Gocovri is a Parkinson's disease product that is an amantadine extended-release formulation, an NMDA receptor antagonist. Onapgo is an apomorphine continuous subcutaneous infusion, a dopamine D1/D2 receptor agonist, which received FDA approval on February 4, 2025. In 2025, Sage Therapeutics' Zurzuvae, acquired by Supernus, is a zuranolone, a GABA-A receptor positive allosteric modulator, which was approved by the FDA on August 4, 2023, for the treatment of adults with postpartum depression and is co-commercialized by Biogen (BIIB) in the United States. The combination of Indivior's addiction treatment sales force and Supernus' CNS product portfolio will reduce single-product risk and increase the utilization of the sales infrastructure targeting specialists.

Market and Execution Risks

The global market for opioid use disorder treatments was approximately $3.9 billion in 2025, and the ongoing opioid crisis in the United States and the adoption of correctional facilities and organized healthcare systems support the demand for long-acting buprenorphine. However, Brixadi's flexible weekly and monthly dosing options and lower-priced generic oral formulations increase price and access competition for Sublocade. The combined company is structured to increase short-term profitability by focusing on expanding the prescriptions for already-approved Sublocade, Qelbree, Zurzuvae, and Onapgo and eliminating redundant costs rather than relying on research and development success. The closing of the transaction, the $1 billion dividend, and the financial capacity and the speed at which the $125 million in synergies are achieved will determine the post-merger per-share value and re-evaluation of the valuation.